Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

MicroMed Cardiovascular CEO

You may also be interested in...



Thermo Fisher Underscores Allergy Test Opportunity With $3.5 Bil. Phadia Deal

Thermo Fisher Scientific wants to claim a dominant share of the budding in vitro allergy testing market segment in the U.S. with its planned $3.5 billion acquisition of Swedish firm Phadia, announced May 19.

People In Brief

PCORI executive director

People In Brief

Medingo nabs Medtronic alum: Israeli insulin-dispensing patch pump maker appoints former Medtronic VP Pete Wehrly as president and CEO, effective Nov. 2. Wehrly, who previously ran Medtronic's spinal and biologics business and its Sofamor Danek orthopedic unit, replaces company founder Ofer Yodfat, who will remain on as general manager. The appointment coincides with Medingo's establishment of U.S.-based operations

Latest News
See All
UsernamePublicRestriction

Register

MT030226

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel